Ethnic Status and Mutation Prevalence - Hereditary Breast Cancer

	Tweet

Ethnic status strongly influences the probability of detecting a mutation in BRCA1 or BRCA2. In the United States, Jewish women do not, as a group, manifest a significantly increased risk for breast or ovarian cancer; however, Jewish women who have a close relative affected with breast or ovarian cancer appear to be at greater risk than non-Jewish women with an affected relative.

It has been suggested that the increased familial risk of breast or ovarian cancer among Jewish women is related to an increased prevalence of BRCA1 or BRCA2 mutations in this population.

In 1996, Tonin et al described a recurring BRCA1 mutation (185delAG, also known as 187delAG) in breast cancer patients of Ashkenazi (Central and Eastern European Jewish) descent (reviewed in ref. 16). 

Several groups quickly demonstrated that up to 20% of Ashkenazi women with early-onset breast cancer carry this mutation. Soon thereafter, a recurring BRCA2 mutation (6174delT) was identified in an additional 8% of Ashkenazi women with early-onset breast cancer.

The high prevalence of these specific mutations among young breast cancer patients of Ashkenazi descent is a reflection of a remarkably high prevalence of these same changes in the Ashkenazi population as a whole. Population studies have indicated that 2.5% of unselected individuals of Ashkenazi descent carry one of three recurrent mutations (the two described above or a third, BRCA1 5382insC, also known as 5385insC). This high population prevalence is presumably the result of a “founder effect” in the ancestral European population. Unpublished series of Ashkenazi women with breast cancer (not selected for age at onset or family history) indicate that approximately 10% of women from this population have one of these three germline mutations.

Founder mutations are even more common in women of Ashkenazi descent with ovarian cancer. In unselected series, nearly 28% of Ashkenazi women with ovarian cancer (all ages) have one of the two BRCA1 mutations, and approximately 12% of those tested have BRCA2 6174delT. Collaborative series have shown that families of Ashkenazi descent with two or more breast cancers (at least one occurring before age 50) have a 29% likelihood of transmitting a founder mutation. If there is at least one case of ovarian cancer in the family, the probability of finding one of these mutations rises to 73%.

Interestingly, mutations appear to be less common in Ashkenazi women with DCIS (although still greater than in the general Ashkenazi population) and do not appear to occur with increased frequency in women with borderline ovarian tumors. Although these specific mutations are responsible for the majority of BRCA1 or BRCA2 alterations identified in this population, it is important to note that other mutations have been described in individuals of Ashkenazi descent. Hence, Ashkenazi families with pedigrees that are strongly suggestive of a hereditary breast or breast-ovarian cancer syndrome, but who do not appear to transmit one of the three founder mutations, should be offered more complete analysis of BRCA1 and BRCA2.

Mark E. Robson
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 2003

References

RELATED STORIES:
Nipple Problems and Discharge   Sexuality and Breast Cancer Survivorship   Biology of High Risk Benign Breast Lesions - Introduction   Duct Ectasia   Mammary-Duct Fistula   Duct Papilloma   Chemotherapy in the Adjuvant Setting   Urinary Incontinence in patients with breast cancer   Periductal Mastitis   Fibroadenoma of the Breast   Guidelines and Risk-Based Screening   Probability of Detecting Mutations in BRCA1 or BRCA2   Phyllodes Tumor   Fat necrosis of the breast   Radiation Therapy for Axillary Control   Estrogen Receptor   The surgical management of breast cancer   Hereditary Breast Cancer and the Identification of BRCA1 and BRCA2   Axillary Surgery   Obesity and Breast Cancer   Evaluation of Breast Cancer Screening   Breast Cancer in Black Women

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]